Pre-made Tidutamab benchmark antibody ( Bispecific Mixed mAb and scFv, anti-SSTR2;CD3E therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-570

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-570 Category Tags ,

Product Details

Pre-Made Tidutamab biosimilar, Bispecific Mixed mAb and scFv, Anti-SSTR2;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tidutamab (formerly XmAb 18087) is a humanised, Fc domain-containing, bispecific monoclonal antibody targeting somatostatin receptor 2 (SSTR2) and a cytotoxic T-cell binding domain (CD3), being developed by Xencor, for the treatment of neuroendocrine tumours (NET) and gastrointestinal stromal tumours (GIST).

Products Name (INN Index)

Pre-Made Tidutamab biosimilar, Bispecific Mixed mAb and scFv, Anti-SSTR2;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody

INN Name

Tidutamab

Target

SSTR2,CD3E

Format

Bispecific Mixed mAb and scFv

Derivation

Bispecific antibody

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa,Lambda

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Discontinued

100% SI Structure

None;None

99% SI Structure

None;None

95-98% SI Structure

None;None

Year Proposed

2018

Companies

ICON,Xencor

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Gastrointestinal stromal tumours,Neuroendocrine tumours

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

SSTR2,CD3E

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide